You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMetoclopramide
Accession NumberDB01233  (APRD00665)
TypeSmall Molecule
GroupsApproved, Investigational
Description

A dopamine D2 antagonist that is used as an antiemetic. [PubChem]

Structure
Thumb
Synonyms
2-Methoxy-4-amino-5-chloro-N,N-(dimethylaminoethyl)benzamide
2-methoxy-5-chloroprocainamide
4-amino-5-chloro-2-Methoxy-N-(beta-diethylaminoethyl)benzamide
4-amino-5-chloro-N-(2-(Diethylamino)ethyl)-2-methoxybenzamide
4-amino-5-chloro-N-(2-(Diethylamino)ethyl)-O-anisamide
Elieten
Metoclopramida
Metoclopramidum
Reliveran
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Maxeran 5mg Tabtablet5 mgoralLabs Nordic Laboratories Inc. Subsidary Of M.M.D.C.1984-12-311998-08-12Canada
Maxeran Liqliquid1 mgoralHoechst Marion Roussel Canada Inc.1995-12-312000-07-28Canada
Maxeran-10 (10mg Tablet)tablet10 mgoralHoechst Marion Roussel Canada Inc.1995-12-312000-07-28Canada
Maxeran-5 (5mg Tablet)tablet5 mgoralHoechst Marion Roussel Canada Inc.1996-10-232000-07-28Canada
Metoclopramideinjection, solution5 mg/mLintramuscular; intravenousCardinal Health2010-12-09Not applicableUs
Metoclopramideinjection, solution10 mg/2mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Metoclopramideinjection, solution5 mg/2mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc.2010-05-01Not applicableUs
Metoclopramide Hydrochloride Injectionliquid5 mgintramuscular; intravenousSandoz Canada Incorporated1995-12-31Not applicableCanada
Metoclopramide Hydrochloride Injection Hsliquid5 mgintravenousBioniche Pharma (Canada) Ltd1999-04-192014-09-11Canada
Metoclopramide Omegaliquid5 mgintramuscular; intravenousOmega Laboratories Ltd2001-04-30Not applicableCanada
Metoclopramide Tab 10mgtablet10 mgoralPro Doc Limitee1990-12-312011-07-27Canada
Metoclopramide Tab 5mgtablet5 mgoralPro Doc Limitee1990-12-312011-07-27Canada
Metoniasolution1 mgoralPendopharm Division Of De Pharmascience Inc1997-02-25Not applicableCanada
Metoniatablet10 mgoralPendopharm Division Of De Pharmascience Inc1997-03-24Not applicableCanada
Metoniatablet5 mgoralPendopharm Division Of De Pharmascience Inc1998-04-16Not applicableCanada
Metozolv ODTtablet, orally disintegrating10 mg/1oralSalix Pharmaceuticals, Inc.2009-09-04Not applicableUs
Metozolv ODTtablet, orally disintegrating5 mg/1oralSalix Pharmaceuticals, Inc.2009-09-04Not applicableUs
Nu-metoclopramide-tab 10mgtablet10 mgoralNu Pharm Inc1995-12-312012-09-04Canada
Nu-metoclopramide-tab 5mgtablet5 mgoralNu Pharm Inc1995-12-312012-09-04Canada
Reglantablet10 mg/1oralSTAT Rx USA LLC2010-01-15Not applicableUs
Reglantablet10 mg/1oralANI Pharmaceuticals, Inc.2011-07-05Not applicableUs
Reglantablet5 mg/1oralANI Pharmaceuticals, Inc.2011-07-05Not applicableUs
Reglaninjection, solution5 mg/mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Reglan Inj 5mg/mlliquid5 mgintramuscular; intravenousAyerst Laboratories1992-12-311996-09-10Canada
Reglan Injectable Liq 5mg/mlliquid5 mgintramuscular; intravenousWyeth Ayerst Canada Inc.1994-12-312001-08-03Canada
Reglan Syr 1mg/mlsyrup1 mgoralWyeth Ayerst Canada Inc.1994-12-312000-03-07Canada
Reglan Syrup 1mg/mlsyrup1 mgoralAyerst Laboratories1992-12-311996-09-10Canada
Reglan Tab 10mgtablet10 mgoralAyerst Laboratories1992-12-311999-04-12Canada
Reglan Tab 10mgtablet10 mgoralWyeth Ayerst Canada Inc.1995-12-312002-02-06Canada
Reglan Tab 5mgtablet5 mgoralAyerst Laboratories1993-12-311997-08-15Canada
Reglan-5 Tab 5mgtablet5 mgoralWyeth Ayerst Canada Inc.1996-09-201999-04-12Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-metoclop Tab 10mgtablet10 mgoralApotex Inc1989-12-31Not applicableCanada
Apo-metoclop Tab 5mgtablet5 mgoralApotex Inc1989-12-31Not applicableCanada
Metoclopramideinjection, solution5 mg/mLintramuscular; intravenousTeva Parenteral Medicines, Inc.1991-12-01Not applicableUs
Metoclopramidetablet10 mg/1oralMylan Institutional Inc.2014-01-02Not applicableUs
Metoclopramidetablet5 mg/1oralCardinal Health1993-07-01Not applicableUs
Metoclopramidetablet10 mg/1oralRanbaxy Pharmaceuticals Inc.2009-03-13Not applicableUs
Metoclopramidetablet5 mg/1oralBionpharma Inc.2015-12-15Not applicableUs
Metoclopramidetablet5 mg/1oralAv Kare, Inc.2014-09-30Not applicableUs
Metoclopramidetablet5 mg/1oralSTAT Rx USA LLC2006-08-28Not applicableUs
Metoclopramidetablet10 mg/1oralTeva Pharmaceuticals USA Inc1990-09-30Not applicableUs
Metoclopramidetablet10 mg/1oralREMEDYREPACK INC.2013-03-14Not applicableUs
Metoclopramidetablet5 mg/1oralCardinal Health2011-08-23Not applicableUs
Metoclopramideinjection, solution10 mg/2mLintravenousBD Rx Inc.2013-05-03Not applicableUs
Metoclopramidetablet10 mg/1oralLiberty Pharmaceuticals, Inc.1990-09-30Not applicableUs
Metoclopramidetablet10 mg/1oralPar Pharmaceutical Inc.1985-10-17Not applicableUs
Metoclopramidetablet10 mg/1oralA S Medication Solutions Llc1990-09-30Not applicableUs
Metoclopramidesolution5 mg/5mLoralMorton Grove Pharmaceuticals, Inc.1997-10-31Not applicableUs
Metoclopramidetablet10 mg/1oralAmerican Health Packaging2013-07-23Not applicableUs
Metoclopramidetablet5 mg/1oralCardinal Health2010-10-192015-12-29Us
Metoclopramideinjection5 mg/mLintramuscular; intravenousHeritage Pharmaceuticals Inc.2014-01-03Not applicableUs
Metoclopramidetablet5 mg/1oralRanbaxy Pharmaceuticals Inc.2009-03-13Not applicableUs
Metoclopramidetablet10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1985-10-17Not applicableUs
Metoclopramidetablet5 mg/1oralMylan Institutional Inc.2013-12-30Not applicableUs
Metoclopramidetablet5 mg/1oralCardinal Health2013-12-30Not applicableUs
Metoclopramideinjection, solution5 mg/mLintramuscular; intravenousHospira, Inc.1991-01-17Not applicableUs
Metoclopramidetablet10 mg/1oralPar Pharmaceutical Inc.1985-10-17Not applicableUs
Metoclopramidetablet5 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Metoclopramidesolution5 mg/5mLoralCardinal Health1991-06-01Not applicableUs
Metoclopramidetablet5 mg/1oralUDL Laboratories, Inc.2011-08-232015-12-29Us
Metoclopramidetablet5 mg/1oralRebel Distributors Corp.2008-01-01Not applicableUs
Metoclopramidetablet5 mg/1oralProficient Rx LP1990-09-30Not applicableUs
Metoclopramidetablet10 mg/1oralPreferred Pharmaceuticals, Inc.2009-03-13Not applicableUs
Metoclopramidetablet10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1985-10-17Not applicableUs
Metoclopramidetablet5 mg/1oralUnit Dose Services1993-07-01Not applicableUs
Metoclopramidetablet10 mg/1oralCardinal Health2014-01-02Not applicableUs
Metoclopramidetablet10 mg/1oralCardinal Health2013-07-23Not applicableUs
Metoclopramidetablet10 mg/1oralUDL Laboratories, Inc.2011-08-232015-12-29Us
Metoclopramidetablet10 mg/1oralRebel Distributors Corp.2006-01-01Not applicableUs
Metoclopramidetablet10 mg/1oralActavis Elizabeth LLC1985-10-17Not applicableUs
Metoclopramidetablet10 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Metoclopramidetablet5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-11-18Not applicableUs
Metoclopramidesolution5 mg/5mLoralUnit Dose Services1991-06-01Not applicableUs
Metoclopramideinjection, solution5 mg/mLintramuscular; intravenousCardinal Health2009-09-22Not applicableUs
Metoclopramidetablet10 mg/1oralProficient Rx LP1990-09-30Not applicableUs
Metoclopramidetablet10 mg/1oralPreferred Pharmaceuticals, Inc.2013-04-01Not applicableUs
Metoclopramidetablet10 mg/1oralMc Kesson Contract Packager2013-03-14Not applicableUs
Metoclopramidesolution5 mg/5mLoralPharmaceutical Associates, Inc.1991-06-01Not applicableUs
Metoclopramidetablet10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1985-10-17Not applicableUs
Metoclopramidetablet10 mg/1oralA S Medication Solutions Llc1990-09-30Not applicableUs
Metoclopramidesolution5 mg/5mLoralANI Pharmaceuticals, Inc.2015-05-18Not applicableUs
Metoclopramidetablet5 mg/1oralCarilion Materials Management1993-07-01Not applicableUs
Metoclopramidesolution5 mg/5mLoralPharmaceutical Associates, Inc.1991-06-01Not applicableUs
Metoclopramidetablet10 mg/1oralREMEDYREPACK INC.2013-07-01Not applicableUs
Metoclopramidetablet10 mg/1oralMc Kesson Contract Packaging2011-09-30Not applicableUs
Metoclopramidetablet10 mg/1oralAidarex Pharmaceuticals LLC1990-09-30Not applicableUs
Metoclopramidetablet10 mg/1oralQualitest Pharmaceuticals2006-08-28Not applicableUs
Metoclopramidetablet5 mg/1oralLake Erie Medical DBA Quality Care Products LLC1993-07-01Not applicableUs
Metoclopramidetablet5 mg/1oralPhysicians Total Care, Inc.2003-03-27Not applicableUs
Metoclopramidesolution5 mg/5mLoralANIP Acquisition Company2011-03-10Not applicableUs
Metoclopramidesolution10 mg/10mLoralPrecision Dose Inc.2007-11-262016-02-02Us
Metoclopramidetablet10 mg/1oralApotheca Inc.1990-09-30Not applicableUs
Metoclopramidetablet10 mg/1oralREMEDYREPACK INC.2013-03-14Not applicableUs
Metoclopramidetablet10 mg/1oralCardinal Health2011-08-23Not applicableUs
Metoclopramidetablet10 mg/1oralbryant ranch prepack2009-03-13Not applicableUs
Metoclopramidetablet10 mg/1oralBionpharma Inc.2015-12-15Not applicableUs
Metoclopramidetablet10 mg/1oralAv Kare, Inc.2014-09-30Not applicableUs
Metoclopramidetablet10 mg/1oralSTAT Rx USA LLC2006-08-28Not applicableUs
Metoclopramidetablet5 mg/1oralTeva Pharmaceuticals USA Inc1993-07-01Not applicableUs
Metoclopramidetablet10 mg/1oralREMEDYREPACK INC.2013-05-23Not applicableUs
Metoclopramidetablet5 mg/1oralMc Kesson Contract Packaging2011-10-04Not applicableUs
Metoclopramidetablet10 mg/1oralREMEDYREPACK INC.2013-03-19Not applicableUs
Metoclopramidetablet5 mg/1oralQualitest Pharmaceuticals2006-08-28Not applicableUs
Metoclopramidetablet10 mg/1oralLake Erie Medical DBA Quality Care Products LLC1990-09-30Not applicableUs
Metoclopramidetablet10 mg/1oralPhysicians Total Care, Inc.2003-05-01Not applicableUs
Metoclopramidetablet10 mg/1oralAmerican Health Packaging2016-01-01Not applicableUs
Metoclopramidetablet10 mg/1oralAmerican Health Packaging2005-06-232016-01-05Us
Metoclopramide Hydrochloridetablet10 mg/1oralAphena Pharma Solutions Tennessee, Llc2011-08-22Not applicableUs
Metoclopramide Hydrochloridetablet5 mg/1oralbryant ranch prepack2008-12-23Not applicableUs
Metoclopramide Hydrochloridetablet10 mg/1oralPreferred Pharmaceuticals, Inc.2013-02-06Not applicableUs
Metoclopramide Hydrochloridetablet10 mg/1oralRebel Distributors Corp2011-08-22Not applicableUs
Metoclopramide Hydrochloridesolution5 mg/5mLoralVista Pharm Inc.2010-02-12Not applicableUs
Metoclopramide Hydrochloridetablet10 mg/1oralActavis Pharma, Inc.2011-08-22Not applicableUs
Metoclopramide Hydrochloridetablet5 mg/1oralRebel Distributors Corp2011-08-22Not applicableUs
Metoclopramide Hydrochloridetablet10 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-03-17Not applicableUs
Metoclopramide Hydrochloridetablet10 mg/1oralREMEDYREPACK INC.2011-05-16Not applicableUs
Metoclopramide Hydrochloridetablet, orally disintegrating5 mg/1oralNovel Laboratories, Inc.2014-08-15Not applicableUs
Metoclopramide Hydrochloridetablet5 mg/1oralActavis Pharma, Inc.2011-08-22Not applicableUs
Metoclopramide Hydrochloridetablet5 mg/1oralCardinal Health2011-03-17Not applicableUs
Metoclopramide Hydrochloridetablet5 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-03-17Not applicableUs
Metoclopramide Hydrochloridetablet10 mg/1oralNorthstar Rx LLC2011-03-17Not applicableUs
Metoclopramide Hydrochloridetablet5 mg/1oralREMEDYREPACK INC.2011-09-21Not applicableUs
Metoclopramide Hydrochloridetablet10 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Metoclopramide Hydrochloridetablet, orally disintegrating10 mg/1oralNovel Laboratories, Inc.2014-08-15Not applicableUs
Metoclopramide Hydrochlorideinjection5 mg/mLintravenousCardinal Health1993-12-10Not applicableUs
Metoclopramide Hydrochloridetablet5 mg/1oralNorthstar Rx LLC2011-03-17Not applicableUs
Metoclopramide Hydrochloridetablet, orally disintegrating5 mg/1oralGAVIS Pharmaceuticals, LLC2015-04-06Not applicableUs
Metoclopramide Hydrochloridetablet10 mg/1oralCardinal Health2011-03-17Not applicableUs
Metoclopramide Hydrochloridetablet10 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-08-22Not applicableUs
Metoclopramide Hydrochloridetablet, orally disintegrating10 mg/1oralGAVIS Pharmaceuticals, LLC2015-04-06Not applicableUs
Metoclopramide Hydrochloridetablet10 mg/1oralCardinal Health1985-10-17Not applicableUs
Metoclopramide Hydrochloridetablet5 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2011-08-22Not applicableUs
Metoclopramide Hydrochloridetablet5 mg/1oralDIRECT RX2014-01-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CerucalNot Available
DeganNot Available
ElietenNot Available
MaxeranNot Available
MaxolonNot Available
METOZOLVNot Available
Plasil1Not Available
PlazilinNot Available
PraminNot Available
PrimperanNot Available
PulinNot Available
PylomidNot Available
ReliveranNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Metoclopramide Hydrochloride
Thumb
  • InChI Key: KJBLQGHJOCAOJP-UHFFFAOYSA-N
  • Monoisotopic Mass: 353.127297095
  • Average Mass: 354.273
DBSALT000393
Categories
UNIIL4YEB44I46
CAS number364-62-5
WeightAverage: 299.796
Monoisotopic: 299.14005467
Chemical FormulaC14H22ClN3O2
InChI KeyInChIKey=TTWJBBZEZQICBI-UHFFFAOYSA-N
InChI
InChI=1S/C14H22ClN3O2/c1-4-18(5-2)7-6-17-14(19)10-8-11(15)12(16)9-13(10)20-3/h8-9H,4-7,16H2,1-3H3,(H,17,19)
IUPAC Name
4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
SMILES
CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as aminobenzoic acids and derivatives. These are benzoic acids (or derivative thereof) containing an amine group attached to the benzene moiety.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentAminobenzoic acids and derivatives
Alternative Parents
Substituents
  • 3-halobenzoic acid or derivatives
  • Salicylamide
  • Aminobenzoic acid or derivatives
  • Methoxyaniline
  • Benzamide
  • Aminobenzamide
  • Methoxybenzene
  • Substituted aniline
  • Phenol ether
  • Benzoyl
  • Anisole
  • Halobenzene
  • Chlorobenzene
  • Aniline
  • Alkyl aryl ether
  • Primary aromatic amine
  • Aryl halide
  • Aryl chloride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of gastroesophageal reflux disease (GERD). It is also used in treating nausea and vomiting, and to increase gastric emptying.
PharmacodynamicsMetoclopramide, although chemically related to procainamide, does not possess local anesthetic or antiarrhythmic properties. Metoclopramide is used to enhance GI motility, to treat diabetic gastroparesis, as an antinauseant, and to facilitate intubation of the small bowel during radiologic examination. Metoclopramide may be used to treat chemotherapy-induced emesis and as a radiosensitizing agents in the treatment of non-small cell lung carcinoma and glioblastomas in the future.
Mechanism of actionMetoclopramide inhibits gastric smooth muscle relaxation produced by dopamine, therefore increasing cholinergic response of the gastrointestinal smooth muscle. It accelerates intestinal transit and gastric emptying by preventing relaxation of gastric body and increasing the phasic activity of antrum. Simultaneously, this action is accompanied by relaxation of the upper small intestine, resulting in an improved coordination between the body and antrum of the stomach and the upper small intestine. Metoclopramide also decreases reflux into the esophagus by increasing the resting pressure of the lower esophageal sphincter and improves acid clearance from the esophagus by increasing amplitude of esophageal peristaltic contractions. Metoclopramide's dopamine antagonist action raises the threshold of activity in the chemoreceptor trigger zone and decreases the input from afferent visceral nerves. Studies have also shown that high doses of metoclopramide can antagonize 5-hydroxytryptamine (5-HT) receptors in the peripheral nervous system in animals.
Related Articles
AbsorptionRapidly and well absorbed (oral bioavailability 80±15.5%).
Volume of distribution
  • 4.4±0.65 L/kg
Protein binding30%
Metabolism

Hepatic

Route of eliminationApproximately 85% of the radioactivity of an orally administered dose appears in the urine within 72 hours.
Half life5-6 hr
Clearance
  • 0.67 +/- 0.14 L/hr/kg [infants (0.9-5.4 months) with gastroesophageal reflux (GER)]
ToxicityOral, mouse LD50: 280 mg/kg. Signs of overdose include drowsiness, disorientation, and extrapyramidal reactions.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.979
Blood Brain Barrier+0.9713
Caco-2 permeable+0.8866
P-glycoprotein substrateSubstrate0.7687
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8783
Renal organic cation transporterNon-inhibitor0.7276
CYP450 2C9 substrateNon-substrate0.8602
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.6375
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9099
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6223
Ames testNon AMES toxic0.5378
CarcinogenicityNon-carcinogens0.6142
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6332 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8367
hERG inhibition (predictor II)Inhibitor0.8579
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg
Tabletoral5 mg
Liquidoral1 mg
Injectionintramuscular; intravenous5 mg/mL
Injection, solutionintramuscular; intravenous10 mg/2mL
Injection, solutionintramuscular; intravenous5 mg/2mL
Injection, solutionintramuscular; intravenous5 mg/mL
Injection, solutionintravenous10 mg/2mL
Solutionoral10 mg/10mL
Solutionoral5 mg/5mL
Tabletoral10 mg/1
Tabletoral5 mg/1
Injectionintravenous5 mg/mL
Tablet, orally disintegratingoral10 mg/1
Tablet, orally disintegratingoral5 mg/1
Liquidintramuscular; intravenous5 mg
Liquidintravenous5 mg
Solutionoral1 mg
Syruporal1 mg
Prices
Unit descriptionCostUnit
Metoclopramide hcl powder7.65USD g
Reglan 10 mg tablet1.81USD tablet
Reglan 5 mg tablet1.41USD tablet
Metoclopramide Hydrochloride 5 mg/ml1.39USD ml
Reglan 5 mg/ml vial0.56USD ml
Metoclopramide HCl 5 mg tablet0.43USD tablet
Metoclopramide 5 mg tablet0.33USD tablet
Metoclopramide 10 mg tablet0.28USD tablet
Metoclopramide 5 mg/ml ampul0.28USD ml
Metoclopramide HCl 10 mg tablet0.27USD tablet
Metoclopramide HCl 5 mg/5ml Solution0.06USD ml
Apo-Metoclop 10 mg Tablet0.06USD tablet
Apo-Metoclop 5 mg Tablet0.06USD tablet
Nu-Metoclopramide 10 mg Tablet0.06USD tablet
Nu-Metoclopramide 5 mg Tablet0.06USD tablet
Pms-Metoclopramide 10 mg Tablet0.06USD tablet
Pms-Metoclopramide 5 mg Tablet0.06USD tablet
Pms-Metoclopramide 1 mg/ml Liquid0.04USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6024981 No1998-04-092018-04-09Us
US6221392 No1998-04-092018-04-09Us
US6413549 No1997-07-112017-07-11Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point147.25 °CPhysProp
water solubility200 mg/L (at 25 °C)MERCK (1989)
logP2.62HANSCH,C ET AL. (1995)
logS-3.18ADME Research, USCD
pKa9.27 (at 25 °C)EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.31 mg/mLALOGPS
logP2.18ALOGPS
logP1.4ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)14.49ChemAxon
pKa (Strongest Basic)9.04ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area67.59 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity83.52 m3·mol-1ChemAxon
Polarizability32.7 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

DrugSyn.org

US3177252
General References
  1. JUSTIN-BESANCON L, LAVILLE C: [ANTIEMETIC ACTION OF METOCLOPRAMIDE WITH RESPECT TO APOMORPHINE AND HYDERGINE]. C R Seances Soc Biol Fil. 1964;158:723-7. [PubMed:14186927 ]
  2. Tonini M, Candura SM, Messori E, Rizzi CA: Therapeutic potential of drugs with mixed 5-HT4 agonist/5-HT3 antagonist action in the control of emesis. Pharmacol Res. 1995 May;31(5):257-60. [PubMed:7479521 ]
External Links
ATC CodesA03FA01
AHFS Codes
  • 56:32.00
PDB EntriesNot Available
FDA labelDownload (90.1 KB)
MSDSDownload (73.2 KB)
Interactions
Drug Interactions
Drug
AcepromazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Acepromazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Acetophenazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Metoclopramide.
AmantadineThe therapeutic efficacy of Amantadine can be decreased when used in combination with Metoclopramide.
AmisulprideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amitriptyline.
AmoxapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Amoxapine.
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Metoclopramide.
AripiprazoleThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Aripiprazole.
AsenapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Asenapine.
AtovaquoneThe serum concentration of Atovaquone can be decreased when it is combined with Metoclopramide.
BenzquinamideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Benzquinamide.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Brexpiprazole.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Metoclopramide.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Metoclopramide.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Metoclopramide.
CarphenazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Carphenazine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlormezanone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorprothixene.
CitalopramThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Citalopram.
ClomipramineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Clomipramine.
ClozapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Clozapine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Metoclopramide.
CyclosporineMetoclopramide can cause an increase in the absorption of Cyclosporine resulting in an increased serum concentration and potentially a worsening of adverse effects.
DapsoneThe risk or severity of adverse effects can be increased when Dapsone is combined with Metoclopramide.
DesipramineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Desipramine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Desvenlafaxine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Metoclopramide.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Metoclopramide.
DofetilideMetoclopramide may increase the QTc-prolonging activities of Dofetilide.
DoxepinThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Doxepin.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Metoclopramide.
DuloxetineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Duloxetine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Metoclopramide.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Metoclopramide.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Metoclopramide.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Metoclopramide.
EscitalopramThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Escitalopram.
FencamfamineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fencamfamine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metoclopramide.
FluoxetineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluspirilene.
FluvoxamineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Fluvoxamine.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Metoclopramide.
GoserelinMetoclopramide may increase the QTc-prolonging activities of Goserelin.
HaloperidolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol.
IloperidoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Imipramine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Metoclopramide.
LeuprolideMetoclopramide may increase the QTc-prolonging activities of Leuprolide.
LevomilnacipranThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Levomilnacipran.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Metoclopramide.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Metoclopramide.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Metoclopramide.
LoxapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Loxapine.
LurasidoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Lurasidone.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Metoclopramide.
MesoridazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Mesoridazine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Metoclopramide.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Methotrimeprazine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Metoclopramide.
MifepristoneMifepristone may increase the QTc-prolonging activities of Metoclopramide.
MilnacipranThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Milnacipran.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Metoclopramide.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Metoclopramide.
MolindoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Molindone.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Metoclopramide.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Metoclopramide.
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Metoclopramide.
NortriptylineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Olanzapine.
OndansetronThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Ondansetron.
PaliperidoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Paliperidone.
ParoxetineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Paroxetine.
PerphenazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Metoclopramide.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Metoclopramide.
PimozideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Pimozide.
PiperacetazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Piperacetazine.
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Metoclopramide.
PramipexoleThe therapeutic efficacy of Pramipexole can be decreased when used in combination with Metoclopramide.
PrilocaineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Prilocaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Metoclopramide.
ProchlorperazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Prochlorperazine.
ProcyclidineThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Procyclidine.
PromazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Promethazine.
ProtriptylineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Protriptyline.
QuetiapineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Quetiapine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Metoclopramide.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Metoclopramide.
RemoxiprideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Reserpine.
RisperidoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Risperidone.
RivastigmineThe risk or severity of adverse effects can be increased when Rivastigmine is combined with Metoclopramide.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Metoclopramide.
RopiniroleThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Metoclopramide.
RotigotineThe therapeutic efficacy of Rotigotine can be decreased when used in combination with Metoclopramide.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Metoclopramide.
SertindoleThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sertraline.
Sodium NitriteThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sodium Nitrite.
SulpirideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Metoclopramide.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Metoclopramide.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Metoclopramide.
TetrabenazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Tetrabenazine.
ThioridazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Thiothixene.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Metoclopramide.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metoclopramide.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Metoclopramide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Triflupromazine.
TrimetazidineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trimetazidine.
TrimipramineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Trimipramine.
VenlafaxineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Venlafaxine.
VilazodoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Vortioxetine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Ziprasidone.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Metoclopramide.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Zuclopenthixol.
Food Interactions
  • Food reduces availability, take 30 minutes before meals. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Burger DM, Wiestner T, Hubler M, Binder H, Keiser M, Arnold S: Effect of anticholinergics (atropine, glycopyrrolate) and prokinetics (metoclopramide, cisapride) on gastric motility in beagles and labrador retrievers. J Vet Med A Physiol Pathol Clin Med. 2006 Mar;53(2):97-107. [PubMed:16466463 ]
  4. Hammer D: Gastroesophageal reflux and prokinetic agents. Neonatal Netw. 2005 Mar-Apr;24(2):51-8; quiz 59-62. [PubMed:15835479 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. See RE, Lynch AM, Sorg BA: Subchronic administration of clozapine, but not haloperidol or metoclopramide, decreases dopamine D2 receptor messenger RNA levels in the nucleus accumbens and caudate-putamen in rats. Neuroscience. 1996 May;72(1):99-104. [PubMed:8730709 ]
  3. Harrold MW, Sriburi A, Matsumoto K, Miller DD, Farooqui T, Uretsky N: The interaction of ammonium, sulfonium, and sulfide analogues of metoclopramide with the dopamine D2 receptor. J Med Chem. 1993 Oct 15;36(21):3166-70. [PubMed:8230103 ]
  4. Kishibayashi N, Karasawa A: Stimulating effects of KW-5092, a novel gastroprokinetic agent, on the gastric emptying, small intestinal propulsion and colonic propulsion in rats. Jpn J Pharmacol. 1995 Jan;67(1):45-50. [PubMed:7745844 ]
  5. Chemnitius JM, Haselmeyer KH, Gonska BD, Kreuzer H, Zech R: Indirect parasympathomimetic activity of metoclopramide: reversible inhibition of cholinesterases from human central nervous system and blood. Pharmacol Res. 1996 Jul-Aug;34(1-2):65-72. [PubMed:8981558 ]
  6. Dahlof CG, Hargreaves RJ: Pathophysiology and pharmacology of migraine. Is there a place for antiemetics in future treatment strategies? Cephalalgia. 1998 Nov;18(9):593-604. [PubMed:9876882 ]
  7. Hammer D: Gastroesophageal reflux and prokinetic agents. Neonatal Netw. 2005 Mar-Apr;24(2):51-8; quiz 59-62. [PubMed:15835479 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR4
Uniprot ID:
Q13639
Molecular Weight:
43760.975 Da
References
  1. Guillemot J, Compagnon P, Cartier D, Thouennon E, Bastard C, Lihrmann I, Pichon P, Thuillez C, Plouin PF, Bertherat J, Anouar Y, Kuhn JM, Yon L, Lefebvre H: Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5-HT4) receptors. Endocr Relat Cancer. 2009 Mar;16(1):281-90. doi: 10.1677/ERC-08-0190. Epub 2008 Oct 23. [PubMed:18948374 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Costall B, Gunning SJ, Naylor RJ, Tyers MB: The effect of GR38032F, novel 5-HT3-receptor antagonist on gastric emptying in the guinea-pig. Br J Pharmacol. 1987 Jun;91(2):263-4. [PubMed:2955843 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 11-beta-monooxygenase activity
Specific Function:
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochrome P450 XIB.
Gene Name:
CYP11B1
Uniprot ID:
P15538
Molecular Weight:
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid 11-beta-monooxygenase activity
Specific Function:
Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name:
CYP11B2
Uniprot ID:
P19099
Molecular Weight:
57559.62 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid 17-alpha-monooxygenase activity
Specific Function:
Conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. Catalyzes both the 17-alpha-hydroxylation and the 17,20-lyase reaction. Involved in sexual development during fetal life and at puberty.
Gene Name:
CYP17A1
Uniprot ID:
P05093
Molecular Weight:
57369.995 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on July 24, 2016 01:52